COMPARISON OF COMPOSITE INDICES FOR DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: A POST-HOC ANALYSIS FROM SELECT-PSA 1

被引：1
|
作者：
Smolen, J. S. [1 ]
Lubrano, E. [2 ]
Kishimoto, M. [3 ]
Balanescu, A. [4 ]
Strand, V. [5 ]
Gao, T. [6 ]
Vranich, N. [6 ]
Lippe, R. [7 ]
Tillett, W. [8 ]
机构：
[1] Med Univ Vienna, Med, Vienna, Austria
[2] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy
[3] Kyorin Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan
[4] Carol Davila Univ Med & Pharm, Dept Internal Med & Rheumatol, St Maria Hosp, Bucharest, Romania
[5] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA
[6] AbbVie Inc, Immunol, N Chicago, IL USA
[7] AbbVie Deutschland GmbH & Co KG, Immunol, Wiesbaden, Germany
[8] Royal Natl Hosp Rheumat Dis, Rheumatol, Bath, Avon, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1279
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1025
引用
收藏
页码：824 / 824
页数：1
相关论文
共 50 条
  • [31] DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PSA 1 AND SELECT-PSA 2 STUDIES
    Cai, F.
    Sornasse, T.
    Ruzek, M.
    Fang, Y.
    Kato, K.
    Wung, P.
    McInnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 17 - 18
  • [32] COMPARISON OF CLINICAL AND RADIOLOGIC TREATMENT OUTCOMES FOR PATIENTS WITH MODERATE VS. SEVERE PSORIATIC ARTHRITIS DISEASE ACTIVITY AT BASELINE: POST-HOC ANALYSIS OF ADEPT
    Mease, P. J.
    Kavanaugh, A.
    Perdok, R.
    Kupper, H.
    Lavie, F.
    RHEUMATOLOGY, 2010, 49 : I51 - I51
  • [33] UPADACITINIB RESPONSE RATES IN PATIENTS WITH PSORIATIC ARTHRITIS ENROLLED IN THE SELECT-PSA-1 AND SELECT-PSA-2 TRIALS ASSESSED ACCORDING TO MODIFIED PSARC
    Coates, Laura C.
    Garrood, Toby
    Gullick, Nicola
    Helliwell, Philip
    Kent, Toby
    Marks, Jonathan
    Tillett, William
    Kaur-Papadakis, Daljit
    Tahir, Hasan
    van Haaren, Stijn
    McInnes, Iain
    RHEUMATOLOGY, 2021, 60
  • [34] Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
    Coates, Laura C.
    Garrood, Toby
    Gullick, Nicola
    Helliwell, Philip
    Kent, Toby
    Marks, Jonathan
    Tillett, William
    Kaur-Papadakis, Daljit
    Tahir, Hasan
    van Haaren, Stijn
    McInnes, Iain
    RHEUMATOLOGY, 2022, 62 (01) : E1 - E3
  • [35] Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies
    Schneeberger, Emilce E.
    Citera, Gustavo
    Nash, Peter
    Smolen, Josef S.
    Mease, Philip J.
    Soriano, Enrique R.
    Helling, Claudia
    Szumski, Annette E.
    Mundayat, Rajiv
    de Leon, Dario Ponce
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 58
  • [36] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Bu, X.
    Chen, L.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 836 - 837
  • [37] What Does the Patient Global Assessment (PGA) Mean for Patients with Psoriatic Arthritis? a Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis
    Taelli, Sandra
    Etcheto, Adrien
    Fautrel, Bruno
    Balanescu, Andra
    Braun, Juergen
    Canete, Juan D.
    de Vlam, Kurt
    de Wit, Maarten
    Heiberg, Turid
    Helliwell, Philip S.
    Kalyoncu, Umut
    Kiltz, Uta
    Maccarone, Mara
    Niedermayer, Dora
    Otsa, Kati
    Scrivo, Rossana
    Smolen, Josef S.
    Stamm, Tanja Alexandra
    Veale, Douglas J.
    Kvien, Tore K.
    Gossec, Laure
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S24 - S24
  • [38] Evaluation of Response Using the Psoriatic Arthritis Joint Activity Index Scoring Tool in Patients Treated with Adalimumab: Post-hoc Analysis of the Acclaim Study
    Gladman, D. D.
    Psaradellis, F.
    Illouz, O.
    Sampalis, J. S.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2571 - 2571
  • [39] COMPARISON OF DIFFERENT REMISSION INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM PHASE 3 TOFACITINIB STUDIES
    Schneeberger, E.
    Citera, G.
    Nash, P.
    Smolen, J. S.
    Mease, P. J.
    Soriano, E.
    Helling, C.
    Szumski, A. E.
    Mundayat, R.
    Graham, D.
    Ponce de Leon, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1716 - 1717
  • [40] Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies
    Citera, Gustavo
    Schneeberger, Emilce
    Nash, Peter
    Smolen, Josef
    Mease, Philip
    Soriano, Enrique
    Matulic, Vesna
    Helling, Claudia
    Szumski, Annette
    Mundayat, Rajiv
    Graham, Daniela
    Ponce de Leon, Dario
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345